The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients.
Details
Serval ID
serval:BIB_3E85CEC19B19
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients.
Journal
The British journal of dermatology
ISSN
1365-2133 (Electronic)
ISSN-L
0007-0963
Publication state
Published
Issued date
08/2019
Peer-reviewed
Oui
Volume
181
Number
2
Pages
350-357
Language
english
Notes
Publication types: Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Publication Status: ppublish
Abstract
Survival in mycosis fungoides (MF) is varied and may be poor. The PROCLIPI (PROspective Cutaneous Lymphoma International Prognostic Index) study is a web-based data collection system for early-stage MF with legal data-sharing agreements permitting international collaboration in a rare cancer with complex pathology. Clinicopathological data must be 100% complete and in-built intelligence in the database system ensures accurate staging.
To develop a prognostic index for MF.
Predefined datasets for clinical, haematological, radiological, immunohistochemical, genotypic, treatment and quality of life are collected at first diagnosis of MF and annually to test against survival. Biobanked tissue samples are recorded within a Federated Biobank for translational studies.
In total, 430 patients were enrolled from 29 centres in 15 countries spanning five continents. Altogether, 348 were confirmed as having early-stage MF at central review. The majority had classical MF (81·6%) with a CD4 phenotype (88·2%). Folliculotropic MF was diagnosed in 17·8%. Most presented with stage I (IA: 49·4%; IB: 42·8%), but 7·8% presented with enlarged lymph nodes (stage IIA). A diagnostic delay between first symptom development and initial diagnosis was frequent [85·6%; median delay 36 months (interquartile range 12-90)]. This highlights the difficulties in accurate diagnosis, which includes lack of a singular diagnostic test for MF.
This confirmed early-stage MF cohort is being followed-up to identify prognostic factors, which may allow better management and improve survival by identifying patients at risk of disease progression. This study design is a useful model for collaboration in other rare diseases, especially where pathological diagnosis can be complex.
To develop a prognostic index for MF.
Predefined datasets for clinical, haematological, radiological, immunohistochemical, genotypic, treatment and quality of life are collected at first diagnosis of MF and annually to test against survival. Biobanked tissue samples are recorded within a Federated Biobank for translational studies.
In total, 430 patients were enrolled from 29 centres in 15 countries spanning five continents. Altogether, 348 were confirmed as having early-stage MF at central review. The majority had classical MF (81·6%) with a CD4 phenotype (88·2%). Folliculotropic MF was diagnosed in 17·8%. Most presented with stage I (IA: 49·4%; IB: 42·8%), but 7·8% presented with enlarged lymph nodes (stage IIA). A diagnostic delay between first symptom development and initial diagnosis was frequent [85·6%; median delay 36 months (interquartile range 12-90)]. This highlights the difficulties in accurate diagnosis, which includes lack of a singular diagnostic test for MF.
This confirmed early-stage MF cohort is being followed-up to identify prognostic factors, which may allow better management and improve survival by identifying patients at risk of disease progression. This study design is a useful model for collaboration in other rare diseases, especially where pathological diagnosis can be complex.
Keywords
Adult, Age Factors, Aged, Datasets as Topic, Delayed Diagnosis/statistics & numerical data, Disease Progression, Female, Follow-Up Studies, Humans, International Cooperation, Male, Middle Aged, Mycosis Fungoides/diagnosis, Mycosis Fungoides/mortality, Mycosis Fungoides/pathology, Neoplasm Staging, Prognosis, Prospective Studies, Registries/statistics & numerical data, Risk Factors, Skin/pathology, Skin Neoplasms/diagnosis, Skin Neoplasms/mortality, Skin Neoplasms/pathology
Pubmed
Web of science
Publisher's website
Create date
27/08/2020 13:59
Last modification date
26/06/2024 6:25